CN102207504A - Enzyme-linked immunosorbent assay kit, and preparation method thereof - Google Patents
Enzyme-linked immunosorbent assay kit, and preparation method thereof Download PDFInfo
- Publication number
- CN102207504A CN102207504A CN201110069600XA CN201110069600A CN102207504A CN 102207504 A CN102207504 A CN 102207504A CN 201110069600X A CN201110069600X A CN 201110069600XA CN 201110069600 A CN201110069600 A CN 201110069600A CN 102207504 A CN102207504 A CN 102207504A
- Authority
- CN
- China
- Prior art keywords
- endothelial growth
- growth factor
- vascular endothelial
- kit
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000008157 ELISA kit Methods 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 239000000872 buffer Substances 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 239000013642 negative control Substances 0.000 claims abstract description 6
- 239000013641 positive control Substances 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000003593 chromogenic compound Substances 0.000 claims abstract description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 50
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 50
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 47
- 239000007788 liquid Substances 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 20
- 108091008605 VEGF receptors Proteins 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 241000238631 Hexapoda Species 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- WBODDOZXDKQEFS-UHFFFAOYSA-N 1,2,3,4-tetramethyl-5-phenylbenzene Chemical group CC1=C(C)C(C)=CC(C=2C=CC=CC=2)=C1C WBODDOZXDKQEFS-UHFFFAOYSA-N 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000002965 ELISA Methods 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 238000004393 prognosis Methods 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 239000000370 acceptor Substances 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 abstract description 2
- 238000007789 sealing Methods 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- 239000008176 lyophilized powder Substances 0.000 abstract 2
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 239000012898 sample dilution Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 5
- 150000002460 imidazoles Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 102000058223 human VEGFA Human genes 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018873 Haemoconcentration Diseases 0.000 description 2
- 101150030763 Vegfa gene Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 235000004458 antinutrient Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- ZXKXJHAOUFHNAS-FVGYRXGTSA-N (S)-fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+][C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-FVGYRXGTSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical group CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an enzyme-linked immunosorbent assay (ELISA) kit for detecting vessel endothelial growth factors (VEGF). The kit comprises: an enzyme-linked reaction plate coated with the combination of VEGF acceptors and monoclonal antibodies, enzyme conjugates prepared with horseradish peroxidase (HRP) labeled antibodies and a protective agent, VEGF protein lyophilized powder as a positive control, protein lyophilized powder as a negative control, a sample dilution, PBST concentrated washing liquor, a chromogenic substrate prepared with 3,3<,>,5,5<,>-tetramethylbiphenyl, 2MH2SO4 as a stop buffer, and plate sealing gum paper. The kit can be used in the diagnosis and prognosis of cancer, angiopathy, diabetic retinopathy, and rheumatoid arthritis, with advantages of accurate, specific, sensitive, stable, and convenient.
Description
Technical field
The invention belongs to the biological medicine technology field, relate in particular to the elisa kit for detecting of a kind of detection human vascular endothelial growth factor (VEGF).
The invention still further relates to the preparation method of mentioned reagent box.
Background technology
The development of tumour and transfer are processes multistage, complicated, that have high selectivity, relate to complicated relation between tumour cell and the host, and its mechanism is still very unclear.Progress about new angiogenesis and tumor development, transfer and prognosis relation is rapid in recent years, prove that new angiogenesis is the necessary condition of tumour generation, transfer and metastasis growth, vascular endothelial growth factor (VEGF) is to regulate the most important cell factor that neovascularity generates.Studies show that vascular endothelial growth factor (VEGF) in the growth of vascular system differentiation, have irreplaceable effect (Ferrara et al.Endocr.Rev.1997,18:4-25).
VEGF is a basic protein that molecular weight is the high glycosylation of 45KD, has two identical subunits to form by disulfide-bonded, and isoelectric point is 8.5, and very strong heat-resisting and acidproof ability is arranged.Human VEGF gene has 5 kinds of different isomeride, is respectively VEGF206, VEGF189, VEGF165, VEGF145, VEGF121.
The VEGF high affinity combined sites only is positioned at 3 kinds of vegf receptors on the vascular endothelial cell, i.e. VEGFR-1, VEGFR-2, VEGFR-3, and these 3 kinds of acceptors mainly are distributed in the vascular endothelial cell surface, all are transmembrane receptors.Studies show that, vegf receptor external and VEGF have height affinity (Kendall et al.PNAS USA, 1993,90:10705-9).
VEGF is growth of cancers, the necessary a kind of factor of transfer.Studies show that at present in the various malignant tumours of the mankind (being cancer) disease, the secretion increase of VEGF has ubiquity and popularity.Lot of documents report is arranged, and VEGF is obviously different with concentration among the cancer patient the normal person, the very low or detection of the VEGF concentration among the normal person less than, and VEGF is dense in the cancer patient.Therefore, detect the VEGF concentration in the human blood, can be used in the early stage generaI investigation diagnosis of cancer.On the other hand, the concentration of VEGF in blood of human body changes with the growth and decline situation of tumour.Lump is big, grow when fast, and the haemoconcentration of VEGF is just high; And when tumour during because of chemotherapy or operation " clinical cure ", the haemoconcentration of VEGF reduces.So VEGF must detect the index that can be used as observation of curative effect and prognosis.VEGF is an important component part in the diagnosis of malignant tumor.In addition, blood VEGF level increases and also sees diabetes, vascular inflammation disease, some immunity disease and gestation etc.
(Clin.Chem.1992 38:71) reported ELISA method based on the detection VEGF of immunofluorescence, but its detection sensitivity is lower for Yeo et al..(J Biol.Chem.1992 267:26031) has reported with colorimetric and send out ELISA method into the detection VEGF on basis, but its detection sensitivity only is ng/ml to Houck et al..(Biosci.Biotechnol.Biochem.1995 59:1985) has reported the chemiluminescence ELISA that measures VEGF to Hanatani et al., and the Serum VEGF of measuring the normal person is 8-36ng/l.
Summary of the invention
The detection kit that the purpose of this invention is to provide a kind of enzyme linked immunosorbent detection human vascular endothelial growth factor (VEGF).This kit result is accurately stable, high specificity, highly sensitive, easy to use, be convenient to promote.
Another object of the present invention provides the preparation method of above-mentioned elisa kit for detecting.
For achieving the above object, the invention provides a kind of kit, it consists of:
1. elisa plate; 2. positive control (freeze-drying); 3. negative control (freeze-drying); 4. sample diluting liquid; 5. enzyme joins thing; 6. concentrated cleaning solution; 7. developer A﹠amp; B; 8. stop buffer; 9. shrouding gummed paper.
The invention provides a kind of preparation method of kit, comprise the steps:
(a) with the enzyme-linked reaction plate be solid support, with the vegf receptor of gene engineering expression and monoclonal antibody bag by on solid support;
(b) seal with confining liquid;
(c contacts biological sample and be incubated with vegf receptor and monoclonal antibody on being fixed in elisa plate, and the VEGF in the biological sample combines with vegf receptor and monoclonal antibody specifically;
(d) separating bio sample on vegf receptor and the monoclonal antibody;
(e) the VEGF polyclonal antibody with horseradish peroxidase (HRP) mark detects VEGF, and used chromogenic substrate is 3,3 ', 5,5 '-tetramethyl benzidine (TMB).
The uniqueness of kit of the present invention is that it uses vegf receptor and monoclonal antibody combined packet by elisa plate, can guarantee that the VEGF of reduced levels can be detected by this kit, can have more accurately sample to measure.
VEGF in this kit detection of biological sample is preferably from cancer, angiosis patient or other diseases patient's sample.
Description of drawings
Fig. 1: kit box body of the present invention and composition.
Embodiment
Following embodiment is for the more detailed the present invention of explanation, is confined to this but should not be construed as the present invention.
Embodiment 1:
Kit of the present invention can be following material for example:
(1) vegf receptor and monoclonal antibody combined packet be by elisa plate, and
(2) positive control (vegf protein freeze-dried powder) is 1;
(3) negative control (animal blood serum freeze-dried powder) is 1;
(4) sample diluting liquid: 0.05% Tween-20,1% bovine serum albumin(BSA), 10mM disodium ethylene diamine tetraacetate, 0.05% thimerosal, 0.4M NaCl, pH6.5,1 bottle;
(5) enzyme connection thing: horseradish peroxidase-labeled vascular endothelial growth factor polyclonal antibody, 2 bottles;
(6) concentrated cleaning solution is: 137mM NaCl, 2.7mM KCl, 10mM Na
2HPO
4, 2mMKH
2PO
4, 0.05% Tween-20, Ph7.4,1 bottle;
(7) developer A, B, wherein A liquid level H
2O
2Solution, B liquid is 3,3 ', 5,5 '-the tetramethyl biphenyl amine aqueous solution, each 1 bottle;
(8) stop buffer is 2MH
2SO
4, 1 bottle;
(9) the shrouding gummed paper is 2.
The described various amounts of this example are that the example in 96 holes (12 8 holes or 8 12 holes) calculates with elisa plate all, if the hole count of elisa plate greater or less than 96 holes, then each amount is also more or less corresponding.
This kit outward appearance can be consulted shown in Figure 1.
Its preparation method:
(1) clone of VEGF gene and vegf receptor gene
With human placenta cDNA library is that template is carried out PCR (PCR).According to the report sequences Design primer of VEGF gene, the PCR reaction conditions: 94 ℃ of sex change 40 seconds, 52 ℃ of annealing 1 minute, 72 ℃ were extended 1 minute, 30 back 72 ℃ of insulations of circulation 10 minutes.According to the report sequences Design primer of vegf receptor gene, the PCR reaction conditions: 94 ℃ of sex change 40 seconds, 52 ℃ of annealing 1 minute, 72 ℃ were extended 2 minutes, 30 back 72 ℃ of insulations of circulation 10 minutes.
The fragment of pcr amplification is reclaimed in gel electrophoresis, is cloned among the carrier pMT18-T, and transformed into escherichia coli DH5 α, the extraction recombinant plasmid carries out enzyme and cuts evaluation.The recombinant plasmid called after pMT18-1 of VEGF gene, the recombinant plasmid called after pMT18-2 of vegf receptor gene.Dna sequence analysis is finished by the rich inferior bioengineering in Shanghai company limited.
(2) structure of insect expression vector
With Sal I, BamHI difference digested plasmid pMT18-1 and pMT18-2, reclaim VEGF genetic fragment and vegf receptor genetic fragment respectively.Use Sal I, BamH I digested plasmid pFastBac-HT simultaneously, reclaim the 4.7kb fragment.The VEGF genetic fragment is connected carrier construction pFastBac-1 and pFastBac-2 respectively with the vegf receptor genetic fragment with the 4.7kb fragment.Carry out enzyme with different restriction enzymes and cut evaluation, show that constructed carrier is correct.
Respectively carrier pFastBac-1 and pFastBac-2 are transformed the DH10Bac competent cell.Adopt the screening of blue hickie, after 24 hours hickie is drawn on the new flat board, confirm its whether hickie.Bacterium colony is chosen in the 2mlLB nutrient culture media, 37 ℃, 250rpm shaken cultivation 12 hours.
The plasmid method of extracting in the bacterium liquid of cultivating is as follows:
(a) 1.5ml bacterium liquid is changed in the centrifuge tube, 10, the centrifugal 30s of 000rpm abandons supernatant, and centrifuge tube is stood upside down on paper handkerchief, makes bacterial precipitation dry as far as possible;
(b) add 300 μ l solution I (50mM glucose, 25mM Tris-HCl, 10mM EDTA, pH8.0), mixing vibrates on the earthquake device;
(c) add the solution II that 300 μ l now join (0.2N NaOH, 1%SDS), mixing, room temperature was placed 5 minutes;
(d) add 300 μ l precoolings solution III (5M KAc, pH5.5), ice bath 5 minutes;
(e) 12, centrifugal 15 minutes of 000rpm;
(f) shift in the new centrifuge tube of supernatant to, add the absolute ethyl alcohol of 2 times of volumes, mixing;
(g) 10,000-12, centrifugal 10 minutes of 000rpm;
(h) with 70% and absolute ethanol washing precipitation;
(i) dry up, be dissolved in TE (the 10mM Tris-HCl that 50 μ l add RNase; 1mMEDTA, pH8.0) in, placed one hour in 37 ℃, place-20 ℃ standby.
The plasmid that extracts is carried out PCR identify, the PCR reaction is according to aforesaid method.
(3) transfection insect cell (with the sf9 cell is example, but is not limited only to the sf9 cell, adopts sf21, sf158, c127 cell line can obtain identical effect, in this not narration one by one).
The sf9 cellular incubation is added 15% hyclone, penicillin 50U/ml, streptomysin 50ug/ml in the Grace nutrient solution, transfection method is as follows:
(a) the previous day is assigned to 24 orifice plates with cell in transfection;
(b) transfection is preceding 2 hours, changes fresh serum-free, unparalleled anti-nutrient solution, washes once, adds 500 μ l nutrient solutions then;
(c) add 2 μ l liposomes, the aforesaid recombinant plasmid of 5 μ l respectively in 50 μ l serum-frees, unparalleled anti-nutrient solution, room temperature was placed 5 minutes, and plasmid is joined in the liposome, and room temperature was placed 20 minutes;
(e) previous step is rapid potpourri is added in the cell, 27 ℃ of cultivations;
(f) transfection sopped up nutrient solution after 4 hours, added 1ml and newly rarely had serum, two anti-Grace nutrient solutions are arranged, and cultivated 72 hours for 27 ℃;
(g) transfection is after 72 hours, and whether observe has malicious sign;
(h) will there be the baculoviral supernatant to infect new sf9 cell.
(4) purifying of insect expressing protein (Ni column adsorption method)
(a) preparation of Ni post
(I) get 1ml Ni-NTA in a centrifuge tube, centrifugal 5 minutes of 1500g;
(II) remove supernatant, with Ni-NTA with the lavation buffer solution of 1 times of volume (20mM Tris-HCl, 500mM KCl, the 20mM imidazoles, the 2mM mercaptoethanol, 10% glycerine, pH8.5) resuspended;
(III) with resuspended liquid to going in the post, with the wash buffer balance of 5-10 times of volume.
(b) preparation of cell extract
(I) 500g collected the 50ml cell in centrifugal 5 minutes;
(II) with lysis buffer (50mM Tris-HCl, 100mM KCl, 20mM imidazoles, 5mM mercaptoethanol, 1mM phenylmethylsulfonyl fluoride, pH8.5) re-suspended cell;
(III) 10, centrifugal 10 minutes of 000g transfers to supernatant in the one new pipe.
(c) protein purification
(I) previous step is rapid supernatant is added in the good Ni post of balance;
(II) with the buffer A of 10 times of volumes (20mM Tris-HCl, 500mM KCl, the 20mM imidazoles, the 5mM mercaptoethanol, 10% glycerine pH8.5) is washed post;
(III) with the buffer B of 2 times of volumes (20mM Tris-HCl, 1M KCl, the 20mM imidazoles, the 5mM mercaptoethanol, 10% glycerine pH8.5) is washed post;
(IV) the buffer A with 2 times of volumes washes post;
(V) with 5-10 times of buffer C (20mM Tris-HCl, 100mM KCl, 100mM imidazoles, 5mM mercaptoethanol, 10% glycerine, pH8.5) wash-out, collection eluent;
(VI) detect the concentration and the purity of purified albumen with SDS-PAGE glue.
(5) VEGF MONOCLONAL ANTIBODIES SPECIFIC FOR and purifying
With the mouse is immune animal, and reorganization VEGF165 is that antigen carries out immunity.Tire according to mouse immune, select the highest animal of immunizing potency, get spleen and carry out Fusion of Cells, adopt indirect ELISA method to carry out the screening of positive hybridoma cell strain.Select the positive hole of a cell mass and carry out limiting dilution, have only this clone cell group in the hole, central authorities intensive circular to around spread out.Treat all like this and whole test positive in all holes of limiting dilution, can think that the clone finishes.Secreting resulting antibody by the hybridoma in the source of single cell wherein is monoclonal antibody.Caprylic acid-ammonium sulfate precipitation method monoclonal antibody purification, purity is more than 95%.
(6) VEGF Polyclonal Antibody Preparation, purifying and mark
Stimulate animal with the injection of 5-10mg Bacille Calmette-Guerin with rabbit earlier as immune animal.After one week vegf protein is made Freund's complete adjuvant, adopt subcutaneous multi-point injection to carry out the immunity first time.After 2 weeks, carry out the immunity second time.After 2 weeks, examination blood is also surveyed and is tired.As it is on the low side to tire, and then carries out booster immunization.
Gather tame rabbit whole blood, centrifuging and taking serum.Add saturated ammonium sulfate in serum, the volume ratio of serum and ammonium sulfate is 2: 1, makes the antibody precipitation, centrifuging, and antibody purity reaches more than 98%.
Adopt glutaraldehyde method with horseradish peroxidase (HRP) mark to the VEGF polyclonal antibody.
(7) preparation of kit
The bag of elisa plate is used following steps: antigen is cushioned the certain multiple of liquid dilution with bag, and every hole adds 100 μ l.Bag was placed on ambient temperature overnight then by 2 hours in 37 ℃ of water-baths or the incubator.The PBST cleansing solution is filled it up with in every hole, places about 30 seconds, dries.Every hole adds 120 μ l confining liquids, and room temperature was placed 2 hours.The confining liquid prescription mainly contains BSA, some salts etc.Get rid of confining liquid, pat and remove remaining confining liquid.Dry up on the super-clean bench.Or blow a few hours on the super-clean bench, room temperature is placed and is spent the night then.Pack with vacuum packing machine.
Embodiment 2: the kit using method
1. from taking out required lath with balance to the sealing bag of room temperature, other lath please seal puts back to 4 ℃.
2. staying a hole is blank well, and other each holes add sample diluting liquid 100 μ l (or 2).
3. except that blank well, add negative control 1 hole, positive control 2 holes, each 100 μ l of serum specimen to respective aperture, flick mixing.Seal reacting hole with the shrouding gummed paper, 37 ℃ 60 minutes.
4. wash plate 3 times: (1) automatic washer: get rid of liquid in the most hole, the cleansing solution that require to inject is 350 μ l, injects and sucking-off 15-30 second at interval, washes plate 3 times.(2) wash plate by hand: get rid of liquid in the most hole, every hole adds cleansing solution 350 μ l, leaves standstill after 30 seconds and gets rid of most liquid, repeatedly pats dry on the thieving paper thick, washes 3 times.
5. except that blank well, the enzyme-added thing 200 μ l in every hole (or 4) seal plate hole, 37 ℃ 60 minutes.
6. wash plate 3 times.
7. chromogenic reaction: developer A, each 100 μ l (or 2) of B liquid are added in the reacting hole (comprising blank well) lucifuge color development at room temperature 25 minutes.
8. cessation reaction: every hole (comprising blank well) adds stop buffer 50 μ l (or 1), and mixing is measured the 450nmOD value.
The advantage that the present invention has:
1. high specificity as a result.The present invention adopt vegf receptor and monoclonal antibody for associating encrusting substance bag by elisa plate, therefore, the specificity height of detection VEGF.
2. highly sensitive.Detection sensitivity can be got to the ng/L level.
4. stable.The present invention is in 4 ℃ of preservations, and the term of validity reaches 9-12 month.
5. convenient.The present invention is easy and simple to handle, and required detecting instrument (microplate reader) generally uses at various big hospital and inspection center.
Clinical practice of the present invention
Adopt the present invention to detect 33 routine patients with lung cancer and 46 routine normal persons' serum sample.The result shows: sensitivity is 67%; Specificity is 80%; Crude agreement is 75%; Positive predictive value is 71%.As shown in table 1:
Table 1. vascular endothelial growth factor detection kit clinical practice result
Sensitivity (%)=A/ (A+C) * 100%=67%
Specificity (%)=D/ (D+B) * 100%=80%
Crude agreement (%)=(A+D)/(A+B+C+D) * 100%=75%
Positive predictive value (%)=A/ (A+B) * 100%=71%
Claims (13)
1. elisa kit for detecting is characterized in that this kit comprises:
Elisa plate, positive control, negative control, sample diluting liquid, enzyme connection thing, concentrated cleaning solution, developer, stop buffer and shrouding gummed paper;
Wherein:
Elisa plate is the enzyme-linked reaction plate of vascular endothelial growth factor receptor and monoclonal antibody combined packet quilt;
Enzyme connection thing is a horseradish peroxidase-labeled vascular endothelial growth factor polyclonal antibody.
2. according to the kit of claim 1, it is characterized in that:
Positive control is a vascular endothelial growth factor albumen freeze-dried powder;
Negative control is the animal blood serum freeze-dried powder;
Sample diluting liquid is 0.05% Tween-20,1% bovine serum albumin(BSA), 10mM disodium ethylene diamine tetraacetate, 0.05% thimerosal, 0.4M NaCl, pH6.5;
Concentrated cleaning solution is 137mM NaCl, 2.7mM KCl, 10mM Na
2HPO
4, 2mMKH
2PO
4, 0.05% Tween-20, Ph7.4;
Developer is developer A﹠amp; B, wherein A liquid is H
2O
2Solution, B liquid is 3,3 ', 5,5 '-the tetramethyl biphenyl amine aqueous solution;
Stop buffer is 2MH
2SO
4
3. according to the kit of claim 1, it is characterized in that each amount of substance is a standard with the hole count of elisa plate.
4. according to the kit of claim 1, it is characterized in that described elisa plate is 96 holes.
5. the preparation method of an elisa kit for detecting is characterized in that may further comprise the steps:
(a) with the vascular endothelial growth factor receptor of gene engineering expression and monoclonal antibody bag by on the solid support enzyme-linked reaction plate;
(b) seal with confining liquid;
(c) biological sample is joined in the enzyme-linked reaction plate reacting hole of pre-bag quilt, the vascular endothelial growth factor in the biological sample combines with vascular endothelial growth factor receptor and monoclonal antibody specifically;
(d) detect vascular endothelial growth factor with the vascular endothelial growth factor polyclonal antibody;
(e) chromogenic substrate be 3,3 ', 5,5 '-the tetramethyl biphenyl amine aqueous solution.
6. according to the method for claim 5, it is characterized in that the described monoclonal antibody of step (a) is with vascular endothelial growth factor immune mouse gained.
7. according to the method for claim 5, it is characterized in that the vascular endothelial growth factor receptor insect cell expression of the described gene engineering expression of step (a).
8. according to the method for claim 7, it is characterized in that described insect cell is sf9, sf12, sf158 or c127 cell line.
9. according to the method for claim 7, it is characterized in that the vascular endothelial growth factor receptor of described insect cell expression Ni post purifying.
10. according to the method for claim 5, it is characterized in that the described biological sample of step (c) is serum, blood plasma, cerebrospinal fluid, saliva, tissue extract or the urine of cancer, angiosis, diabetic retinopathy and rheumatoid arthritis patients.
11. the method according to claim 5 is characterized in that, the described vascular endothelial growth factor polyclonal antibody of step (d) prepares the vascular endothelial growth factor of usefulness and also uses Ni post purifying with insect cell expression.
12. the method according to claim 5 is characterized in that, the described polyclonal antibody of step (d) is with vascular endothelial growth factor immunizing rabbit gained.
13. the method according to claim 5 is characterized in that, the described polyclonal antibody horseradish peroxidase-labeled of step (d).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110069600XA CN102207504A (en) | 2011-03-23 | 2011-03-23 | Enzyme-linked immunosorbent assay kit, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110069600XA CN102207504A (en) | 2011-03-23 | 2011-03-23 | Enzyme-linked immunosorbent assay kit, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102207504A true CN102207504A (en) | 2011-10-05 |
Family
ID=44696442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110069600XA Pending CN102207504A (en) | 2011-03-23 | 2011-03-23 | Enzyme-linked immunosorbent assay kit, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102207504A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102323421A (en) * | 2011-05-24 | 2012-01-18 | 北京健平九星生物医药科技有限公司 | Enzyme linked immunosorbent assay kit and preparation method thereof |
| CN102778452A (en) * | 2012-08-08 | 2012-11-14 | 北京健平九星生物医药科技有限公司 | Chemiluminescence detection kit and preparation method thereof |
| CN102798723A (en) * | 2012-08-03 | 2012-11-28 | 北京华创远航科技有限公司 | Chemiluminescence detection kit and preparation method |
| CN102830235A (en) * | 2012-08-28 | 2012-12-19 | 邹检平 | Luminescence detection kit and preparation method thereof |
| CN104040350A (en) * | 2011-12-19 | 2014-09-10 | 弗·哈夫曼-拉罗切有限公司 | Method for the detection of free binding partner of a multispecific binder |
| CN104105966A (en) * | 2012-02-01 | 2014-10-15 | 弗·哈夫曼-拉罗切有限公司 | Method for the detection of a binding partner of a multispecific binder |
| CN104849466A (en) * | 2014-02-14 | 2015-08-19 | 张曼 | Application of urine vitronectin in diagnosis and treatment of type 2 diabetes mellitus combined early renal injury |
| US9488662B2 (en) | 2012-07-13 | 2016-11-08 | Hoffmann-La Roche Ag | Method for the detection of a multispecific binder |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1260492A (en) * | 1999-11-09 | 2000-07-19 | 赵永同 | Tumor prognosis evaluation kit and preparation process thereof |
| CN1352392A (en) * | 2000-11-09 | 2002-06-05 | 武汉市第七医院 | Method and reagent for directy detecting serum hepatitis B virus core antigen |
| CN1399132A (en) * | 2002-06-25 | 2003-02-26 | 上海晶泰生物技术有限公司 | Polynary immunoassay board |
| CN1490407A (en) * | 2003-08-13 | 2004-04-21 | 公安部第二研究所 | Antihuman hemoglobin detection reagent strips and monoclone antibody contained therewith |
| CN1490408A (en) * | 2003-08-13 | 2004-04-21 | 公安部第二研究所 | Antihuman seminal specific protein P30 detection reagent strips and monoclone antibody therewith |
| CN1598586A (en) * | 2004-09-07 | 2005-03-23 | 江苏省农业科学院 | Immune antibody for detecting pesticide organic phosphorus residus and its application |
| CN1677107A (en) * | 2005-03-14 | 2005-10-05 | 江苏省农业科学院 | A kind of immune antibody for detecting polyether antibiotic residue and its application |
| CN1740793A (en) * | 2004-08-25 | 2006-03-01 | 北京健平九星生物医药科技有限公司 | Enzyme-linked assay kit and producing process thereof |
| CN1866019A (en) * | 2006-04-29 | 2006-11-22 | 吴学记 | Quick detection reagent for syphilis leptospira antigen and preparation method thereof |
| CN1966523A (en) * | 2006-11-24 | 2007-05-23 | 东南大学 | Dursban monoclonal antibody preparing method |
| CN101492506A (en) * | 2008-12-05 | 2009-07-29 | 中国人民解放军第四军医大学 | CIAPIN1 monoclone antibody for multidrug resistant differential diagnosis of stomach cancer and method for preparing the same |
| CN101523220A (en) * | 2006-10-04 | 2009-09-02 | 健泰科生物技术公司 | ELISA for VEGF |
| CN101813697A (en) * | 2010-04-09 | 2010-08-25 | 厦门出入境检验检疫局检验检疫技术中心 | Broad-spectrum pesticide residue immunity test strip and preparation method and application thereof |
| CN101845094A (en) * | 2010-02-08 | 2010-09-29 | 福州大学 | Double-cross-linking chemical synthesis method of citrinin-protein-coupled antigen and preparation method of anti-citrinin monoclonal antibody |
| CN101930006A (en) * | 2010-08-05 | 2010-12-29 | 中国农业科学院油料作物研究所 | High-sensitivity immunochromatographic test strip for rapid detection of total aflatoxin and preparation method thereof |
| CN101963619A (en) * | 2010-09-10 | 2011-02-02 | 中国人民解放军第四军医大学 | Method for quantifying and detecting recombinant protein containing green fluorescent protein fusion tag |
| CN101968488A (en) * | 2010-10-26 | 2011-02-09 | 吉林大学 | Colloidal gold fast diagnostic test strip of goose paramyxovirus disease |
-
2011
- 2011-03-23 CN CN201110069600XA patent/CN102207504A/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1260492A (en) * | 1999-11-09 | 2000-07-19 | 赵永同 | Tumor prognosis evaluation kit and preparation process thereof |
| CN1352392A (en) * | 2000-11-09 | 2002-06-05 | 武汉市第七医院 | Method and reagent for directy detecting serum hepatitis B virus core antigen |
| CN1399132A (en) * | 2002-06-25 | 2003-02-26 | 上海晶泰生物技术有限公司 | Polynary immunoassay board |
| CN1490407A (en) * | 2003-08-13 | 2004-04-21 | 公安部第二研究所 | Antihuman hemoglobin detection reagent strips and monoclone antibody contained therewith |
| CN1490408A (en) * | 2003-08-13 | 2004-04-21 | 公安部第二研究所 | Antihuman seminal specific protein P30 detection reagent strips and monoclone antibody therewith |
| CN1740793A (en) * | 2004-08-25 | 2006-03-01 | 北京健平九星生物医药科技有限公司 | Enzyme-linked assay kit and producing process thereof |
| CN1598586A (en) * | 2004-09-07 | 2005-03-23 | 江苏省农业科学院 | Immune antibody for detecting pesticide organic phosphorus residus and its application |
| CN1677107A (en) * | 2005-03-14 | 2005-10-05 | 江苏省农业科学院 | A kind of immune antibody for detecting polyether antibiotic residue and its application |
| CN1866019A (en) * | 2006-04-29 | 2006-11-22 | 吴学记 | Quick detection reagent for syphilis leptospira antigen and preparation method thereof |
| CN101523220A (en) * | 2006-10-04 | 2009-09-02 | 健泰科生物技术公司 | ELISA for VEGF |
| CN1966523A (en) * | 2006-11-24 | 2007-05-23 | 东南大学 | Dursban monoclonal antibody preparing method |
| CN101492506A (en) * | 2008-12-05 | 2009-07-29 | 中国人民解放军第四军医大学 | CIAPIN1 monoclone antibody for multidrug resistant differential diagnosis of stomach cancer and method for preparing the same |
| CN101845094A (en) * | 2010-02-08 | 2010-09-29 | 福州大学 | Double-cross-linking chemical synthesis method of citrinin-protein-coupled antigen and preparation method of anti-citrinin monoclonal antibody |
| CN101813697A (en) * | 2010-04-09 | 2010-08-25 | 厦门出入境检验检疫局检验检疫技术中心 | Broad-spectrum pesticide residue immunity test strip and preparation method and application thereof |
| CN101930006A (en) * | 2010-08-05 | 2010-12-29 | 中国农业科学院油料作物研究所 | High-sensitivity immunochromatographic test strip for rapid detection of total aflatoxin and preparation method thereof |
| CN101963619A (en) * | 2010-09-10 | 2011-02-02 | 中国人民解放军第四军医大学 | Method for quantifying and detecting recombinant protein containing green fluorescent protein fusion tag |
| CN101968488A (en) * | 2010-10-26 | 2011-02-09 | 吉林大学 | Colloidal gold fast diagnostic test strip of goose paramyxovirus disease |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102323421A (en) * | 2011-05-24 | 2012-01-18 | 北京健平九星生物医药科技有限公司 | Enzyme linked immunosorbent assay kit and preparation method thereof |
| CN104040350B (en) * | 2011-12-19 | 2016-05-18 | 弗·哈夫曼-拉罗切有限公司 | The method of working together for detection of the free combination of polyspecific bond |
| CN104040350A (en) * | 2011-12-19 | 2014-09-10 | 弗·哈夫曼-拉罗切有限公司 | Method for the detection of free binding partner of a multispecific binder |
| CN104105966A (en) * | 2012-02-01 | 2014-10-15 | 弗·哈夫曼-拉罗切有限公司 | Method for the detection of a binding partner of a multispecific binder |
| US10761097B2 (en) | 2012-02-01 | 2020-09-01 | Hoffmann-La Roche Inc. | Method for the detection of a binding partner of a multispecific binder |
| US9488662B2 (en) | 2012-07-13 | 2016-11-08 | Hoffmann-La Roche Ag | Method for the detection of a multispecific binder |
| CN102798723B (en) * | 2012-08-03 | 2015-05-20 | 北京健平九星生物医药科技有限公司 | Chemiluminescence detection kit and preparation method |
| CN102798723A (en) * | 2012-08-03 | 2012-11-28 | 北京华创远航科技有限公司 | Chemiluminescence detection kit and preparation method |
| CN102778452A (en) * | 2012-08-08 | 2012-11-14 | 北京健平九星生物医药科技有限公司 | Chemiluminescence detection kit and preparation method thereof |
| CN102830235B (en) * | 2012-08-28 | 2015-08-12 | 邹检平 | A kind of luminescence detection kit and preparation method thereof |
| CN102830235A (en) * | 2012-08-28 | 2012-12-19 | 邹检平 | Luminescence detection kit and preparation method thereof |
| CN104849466A (en) * | 2014-02-14 | 2015-08-19 | 张曼 | Application of urine vitronectin in diagnosis and treatment of type 2 diabetes mellitus combined early renal injury |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11994343B2 (en) | 2019-03-14 | 2024-05-28 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102207504A (en) | Enzyme-linked immunosorbent assay kit, and preparation method thereof | |
| CN102426240B (en) | Enzyme-linked detection kit and preparation method thereof | |
| TR201809424T4 (en) | Risperidone and paliperidone haptens. | |
| CN102830235B (en) | A kind of luminescence detection kit and preparation method thereof | |
| CN112285348B (en) | Electrochemical luminescence immunoassay kit for antigen protein expressed by new coronavirus vaccine | |
| CN104711279B (en) | It is prepared by a kind of VEGF detection kit and its raw material | |
| CN101929999B (en) | Kit for detecting anti-moesin antibody | |
| CN103045541A (en) | Hybridoma cell strain and monoclonal antibody of anti-heart-type fatty acid-binding protein generated by same | |
| CN102435743B (en) | ELISA detection kit and preparation method thereof | |
| CN102798723B (en) | Chemiluminescence detection kit and preparation method | |
| CN114478785A (en) | Mouse-derived monoclonal antibody of anti-human CHI3L1 and application | |
| CN1316249C (en) | Enzyme-linked assay kit and producing process thereof | |
| CN102439447A (en) | Method for detecting substance in biological sample | |
| CN117447602A (en) | Antibodies to porcine IgM and uses thereof | |
| CN106771218A (en) | A kind of kit of p24 antigens of detection HIV 1 and its application | |
| CN103074303A (en) | Hybridoma cell strain generating anti-human NGAL specific monoclonal antibody, monoclonal antibody generated by same and application | |
| CN109142738A (en) | Marker and its application of the ECM1 as Serologic detection liver fibrosis | |
| CN102323421A (en) | Enzyme linked immunosorbent assay kit and preparation method thereof | |
| CN102539778A (en) | Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha | |
| CN102854322A (en) | Vascular endothelial growth factor (VEGF) receptor enzyme linked diagnosis kit and preparation method thereof | |
| CN102778452A (en) | Chemiluminescence detection kit and preparation method thereof | |
| CN107746430B (en) | Preparation and application of GP 73C-terminal antigen | |
| CN102887944A (en) | Chlamydia pneumonia antigen, method for preparing antigen, fast detection method and reagent for detecting anti-chlamydia pneumonia antibody by utilizing antigen | |
| CN102818896B (en) | Detection method of nitration modification sites based on specific antibodies and antibody capable of specifically recognizing succinyl-CoA: 3-oxoacid CoA transferase (SCOT) nitration sites | |
| CN105001342A (en) | Recombinant human autoantigen SSB-La |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING JIANPING JINXIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING HUACHUANG YUANHANG TECHNOLOGY CO.,LTD. Effective date: 20140129 |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140129 Address after: 100085 A204 room, Zhongguancun biological medicine Park, No. 5, Pioneer Road, Beijing, Haidian District Applicant after: BEIJING HUACHUANG YUANHANG TECHNOLOGY CO., LTD. Address before: 100085 Zhongguancun biological medicine Park, No. 5, Pioneer Road, Beijing, Haidian District, A204 Applicant before: Beijing Huachuang Yuanhang Technology Co.,Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20111005 |